Showing results (41-50 of 109) with videos related to
Sort By:
Pageof 11
Arthritis Care & Research|November 9, 2020
Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and PerspectivesSusan J Bartlett, Anna Kristina Gutierrez, Kathleen M Andersen, et al.Rheumatology (Oxford, England)|January 20, 2021
Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarkingClifton O Bingham, Alessandra L Butanis, Ana Maria Orbai, et al.Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.The Journal of Rheumatology|August 3, 2017
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic ArthritisWilliam Tillett, Emma Dures, Sarah Hewlett, et al.RMD Open|March 12, 2016
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain setUmut Kalyoncu, Alexis Ogdie, Willemina Campbell, et al.RMD Open|January 31, 2024
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritisLaure Gossec, Ana-Maria Orbai, Laura C Coates, et al.Journal of Patient-Reported Outcomes|February 22, 2019
PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritisClifton O Bingham Iii, Anna Kristina Gutierrez, Alessandra Butanis, et al.The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.Current Therapeutic Research, Clinical and Experimental|September 28, 2020
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic ArthritisDafna D Gladman, Ana-Maria Orbai, Juan Gomez-Reino, et al.The Journal of Rheumatology|January 15, 2025
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic ArthritisSarah M Yazji, Philip S Helliwell, Andra Balanescu, et al.Pageof 11